Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan [3]

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 650-

  Kramar, Andrew ^a   Gourgou Bourgade, Sophie ^a   Ychou, Marc ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DOSE RESPONSE; HUMAN; LETTER; METASTASIS; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; BLOOD; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; MONITORING; NOTE; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MONITORING, PHYSIOLOGIC; NEUTROPENIA; REPRODUCIBILITY OF RESULTS;

EID: 14544291538     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.163     Document Type: Letter

References (2)

1. Meyerhardt JA, Kwok A, Ratain MJ, et al: Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 22:1439-1446, 2004
2. Ychou M, Raoul JL, Desseigne F, et al: High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 50:383-391, 2002